Antitumor Activity Seen With Keytruda in mCRPC

]]>(MedPage Today) -- Pembrolizumab (Keytruda) monotherapy demonstrated antitumor activity with manageable safety in a small subgroup of men with previously treated metastatic castrate-resistant prostate cancer (mCRPC), researchers found.Results...